HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE METASTATIC BREAST CANCER
Clinical trials for HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE METASTATIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE METASTATIC BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for Hard-to-Treat breast cancer
Disease control OngoingThis phase 3 study tests a drug called sacituzumab govitecan (Trodelvy) against standard chemotherapy in 331 Asian patients with HR+/HER2- metastatic breast cancer who have already tried at least two prior chemotherapies. The goal is to see if the new drug can delay cancer growth…
Matched conditions: HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE METASTATIC BREAST CANCER
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug cocktails aim to tame metastatic breast cancer
Disease control OngoingThis early-phase trial tests the safety of combining the targeted drug abemaciclib with various other breast cancer treatments (like letrozole, tamoxifen, or trastuzumab) in 198 people whose breast cancer has spread. The goal is to find safe combinations that may help control the…
Matched conditions: HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE METASTATIC BREAST CANCER
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:15 UTC
-
New drug shows promise in slowing advanced breast cancer
Disease control OngoingThis phase 3 study tests whether the drug sacituzumab govitecan (Trodelvy) can help people with a common type of advanced breast cancer (HR+/HER2-) live longer without their cancer growing. About 654 participants will receive either the new drug or one of three standard chemother…
Matched conditions: HORMONE RECEPTOR-POSITIVE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE METASTATIC BREAST CANCER
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC